Skip to content

Characterization of Visual Characteristics in Allergic Contact Dermatitis Using the Skincam® Tool

Characterization of Visual Characteristics in Allergic Contact Dermatitis Using the Skincam® Tool

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06351449
Acronym
PatchCam
Enrollment
500
Registered
2024-04-08
Start date
2024-04-15
Completion date
2027-04-30
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Contact Dermatitis

Keywords

Allergic contact dermatis (ACD), Patch Test, Photographs, SkinCams

Brief summary

Contact dermatitis (CD) is a common inflammatory skin disease, affecting approximately 15-20% of the general population in industrialized countries and ranking first among occupational diseases in many European countries. The patch test method aims at reproducing the eczematous lesions by applying occlusive patches containing the suspected allergens to the patient's healthy skin. It requires experienced medical staff to read the reaction. Newtones Technologies society has developed a new tool, the SkinCam®, able to capture high resolution cross and parallel images, allowing a quantification of color and relief of skin. This study aims to illustrate patch test results, describing skin appearance (color, roughness, shine), using photographs taken by the SkinCam®.

Detailed description

Contact dermatitis (CD) is a common inflammatory skin disease, affecting approximately 15-20% of the general population in industrialized countries and ranking first among occupational diseases in many European countries. Allergic contact dermatitis (ACD) typically presents as a severe skin inflammation with redness, edema, oozing and crusting. It is characterized by a delayed type IV hypersensitivity response mediated by allergen-specific T cells in sensitized individuals. Current diagnosis relies on clinical investigations by diagnostic patch testing with suspected allergenic chemicals. The patch test method aims at reproducing the eczematous lesions by applying occlusive patches containing the suspected allergens to the patient's healthy skin. It requires experienced medical staff to read the reaction. Newtones Technologies society has developed a new tool, the SkinCam®, able to capture high resolution cross and parallel images, allowing a quantification of color and relief of skin. This study aims to illustrate patch test results, describing skin appearance (color, roughness, shine), using photographs taken by the SkinCam®.

Interventions

OTHERThe patch under study is photographed using the SkinCam®

Unlike standard care, the patch under study is photographed using the SkinCam® and not a standard camera. The shooting and photographic remain similar to that of standard care, with only the camera used being changed.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient, male or female, over 18 years of age * Patients called for reading patch test, applied 72 or 96 hours ago * Patients agreeing to have unidentified photographs of patchs tests * Patient affiliated to or benefiting from a social security regime * Patient having been informed and not having opposed

Exclusion criteria

* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant woman

Design outcomes

Primary

MeasureTime frameDescription
To highlight characteristics of allergic contact dermatitis (ACD)one dayTo highlight characteristics of allergic contact dermatitis (ACD), illustrating visually positive patch tests (+, ++, +++) with numerical parameters (colorimetry, shine and roughness)

Contacts

Primary ContactAudrey NOSBAUM, MD
audrey.nosbaum@chu-lyon.fr418861572
Backup ContactFlorence HACARD, MD
florence.hacard@chu-lyon.fr4 78 86 15 72

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026